The biochemistry of rapid replication
Replikins Logo

home
right
right
right
right
right
right
right
home

  BUSINESS WEEK, 9-5-09 "FLU-FIGHTING TECH"

See http://images.businessweek.com/ss/09/05/0506_tech_tracking_epidemics/4.htm

"Software and hardware from Google, IBM, and other tech titans is helping doctors and researchers monitor and combat the spread of H1N1 swine flu and other ...

Flu-Fighting Tech
REPLIKINS (slide 4 of 13)

It takes six to nine months to develop a conventional flu vaccine and much of the wait stems from how long it takes to grow the virus in chicken eggs and then harvest it. But a Boston-based company called Replikins says it can reduce the lag time by using genetic information about the virus to prepare a synthetic vaccine. Replikins scientists, who warned of a potential outbreak of H1N1 a year before it occurred, say they have a synthetic vaccine ready for testing now. "

REPLIKINS PRESS RELEASE No. 18 April 7, 2008
H1N1 Influenza Virus with Highest Replikin Count™ Since the 1918 Pandemic Identified in the U.S. and Austria (April 7, 2008)

See also http://www.medicalnewstoday.com/articles/103052.php

Replikins, Ltd. has found that the Replikin Count™ of the H1N1 strain of influenza virus has recently increased to 7.6 (plus/minus 1.4), its highest level since the 1918 H1N1 pandemic (p value less than 0.001). A rising Replikin Count of a particular influenza strain, indicating rapid replication of the virus, is an early warning which has been followed consistently by an outbreak of the specific strain. The current increase appears to be specific to H1N1; there was a concurrent 80% decline in the Replikin CountTM of H3N2, for instance.

Boston, MA (PRWeb) April 7, 2008 -- Replikins, Ltd. has found that the Replikin Count™ of the H1N1 strain of influenza virus has recently increased to 7.6 (plus/minus 1.4), its highest level since the 1918 H1N1 pandemic (p value less than 0.001). A rising Replikin Count of a particular influenza strain, indicating rapid replication of the virus, is an early warning which has been followed consistently by an outbreak of the specific strain. The current increase appears to be specific to H1N1; there was a concurrent 80% decline in the Replikin Count of H3N2, for instance.

The current H1N1 appears to be rapidly replicating simultaneously in the U.S. and Austria. It may succeed H5N1 as the leading candidate for the next expected overdue pandemic. However, the same virus replikin structures detected by FluForecast® software in all three previous pandemics, namely 1918 H1N1, 1957 H2N2, and 1968 H3N2, as well as in H5N1, have not yet been detected in the currently evolving H1N1.

There is evidence that many factors, including virus structure, host receptivity, and the environment, together with infectivity and rapid replication, need to converge for a pandemic to occur. For H5N1, the high human mortality rate, which peaked at over 80% in 2006-07 in Indonesia, as well as current low infectivity, both appear to limit H5N1's ability to produce a pandemic. Furthermore, the H5N1 rapid replication cycle which began in 1996 now appears to be over. The H5N1 virus produced less than 300 World Health Organization confirmed deaths over the past 10 years.

On the other hand, H1N1, with an estimated human mortality rate of only 2.5 to 10%, but with much higher infectivity, produced an estimated 50 million deaths in the 1918 pandemic. A number of countermeasures exist today which did not exist in 1918, however. Among these is Replikins' ability to manufacture synthetic vaccines based on current sequences, with a seven day production turnaround.


Contact Information
SAM BOGOCH
Replikins, Ltd.
http://www.replikins.com
646-320-5910

Learn more  

Dr. Sanjay Gupta of CNN reports on Replikins

Synthetic flu vaccine option?

2009 report on Replikins and the potential of synthetic vaccine technology to improve on traditional vaccine approaches.

 

The Science:
Replikins in H1N1

Hemagglutinin

A recent Nature Precedings paper shows the location of Replikins peptides on the surface of the active Hemagglutinin portion of the H1N1 virus.